Evaluation of @entity5 metastasis-associated markers for molecular classification in XXXX with @entity1721 .

@entity1 @entity7 @entity5 @entity4910 @entity1721 @entity12020
UNASSIGNED: This study aims to ascertain the relationship of @entity5 metastasis-associated markers @entity4910 , @entity12020 ( @entity12020 ) and @entity7 ( @entity7 ) with the clinicopathologic features and prognosis of @entity1 with @entity1721 ( @entity1721 ), and to investigate their value in @entity1721 molecular classification. The expression of @entity4910 , @entity12020 and @entity7 in 100 specimens from @entity1 and 20 from normal esophageal mucosa were detected by immunohistochemistry. The relationship of their expression with prognosis of the @entity1 with @entity1721 was evaluated by Cox regression model and Kaplan-Meier survival curve analysis. High levels of expression of @entity4910 , @entity12020 , and @entity7 were observed in 61 (61%), 53 (53%), 49 (49%) cases, respectively. Univariate survival analysis indicated that the levels of expression of @entity4910 , @entity12020 and @entity7 were associated with survival (all P-value < 0.05). Multivariate analysis indicated that @entity4910 and @entity7 were independent prognostic factors affecting the three-year survival rate of @entity1 (P = 0.001, 0.017, respectively). Furthermore, high level expression of @entity4910 , @entity12020 and @entity7 in stage I @entity1 was found associated with poor three-year survival rate (all P-value < 0.05). The prognosis probably was favorable for @entity1 with low expression of @entity4910 even in stage III, or @entity7 even in stage IV. Tumor metastasis-associated markers such as @entity4910 and @entity7 may be independent prognostic factors affecting survival rate of postoperative @entity1721 @entity1 . It is possible to judge prognosis better and tailor treatments to each individual @entity1 when these markers were applied to @entity1721 molecular classification.
